Longitudinal Evaluation and Risk Factors of Lipodystrophy and Associated Metabolic Changes in HIV-Infected Children

Abstract

Puberty seems to be the time when HIV-infected children taking potent antiretroviral therapy are more likely to develop lipodystrophy and metabolic complications, especially in children with a severe underlying HIV infection. Once developed, lipodystrophy and metabolic changes seem to be extremely stable with time.